alendronate has been researched along with Rachitis in 2 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report here the use of oral alendronate for the treatment of hypercalcemia due to vitamin D intoxication in a 7 month-old infant with nephrocalcinosis." | 7.73 | Oral alendronate therapy for severe vitamin D intoxication of the infant with nephrocalcinosis. ( Atabek, ME; Pirgon, O; Sert, A, 2006) |
| " We report here the use of oral alendronate for the treatment of hypercalcemia due to vitamin D intoxication in a 7 month-old infant with nephrocalcinosis." | 3.73 | Oral alendronate therapy for severe vitamin D intoxication of the infant with nephrocalcinosis. ( Atabek, ME; Pirgon, O; Sert, A, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eswarakumar, A | 1 |
| Robinson, C | 1 |
| Carpenter, TO | 1 |
| Atabek, ME | 1 |
| Pirgon, O | 1 |
| Sert, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Post-Cardiac Surgery Vitamin D Deficiency in Children With Congenital Heart Disease: A Pilot Dose Evaluation Randomized Controlled Trial[NCT01838447] | Phase 2 | 46 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Blood 25OHD will be measured to determine vitamin D deficiency, with a concentration below 50 nmol/L used to define deficiency. A PICU admission blood sample could not be obtained for one patient in the Usual Care Group and one patient in the High Dose Group, thus the total number analyzed differs from the full sample size. (NCT01838447)
Timeframe: 1 day (On admission to the pediatric intensive care unit (PICU) following CHD surgery)
| Intervention | nmol/L (Mean) |
|---|---|
| Usual Care Group | 34.8 |
| High Dose Group | 52.0 |
Hypercalcemia will be defined as an ionized calcium level above 1.40 mmol/L; or above 1.45 mmol/L for children under 8 weeks. Hypercalcemia will be evaluated in blood collected immediately before CHD surgery and throughout the post-operative course (measurements are standard of care). (NCT01838447)
Timeframe: Immediately before surgery, on admission to the PICU following CHD surgery, and on post-operative days 1,3,5 & 10
| Intervention | No. participants with hypercalcemia (Number) |
|---|---|
| Usual Care Group | 0 |
| High Dose Group | 0 |
Primarily, post-operative catecholamine requirements during the PICU admission will be evaluated as a dichotomous variable (yes/no). If a difference is noted in the primary analysis, inotrope requirements will be determined using the inotrope score, evaluated as the maximum score and in a time to event approach (off all inotropes, score of zero) (NCT01838447)
Timeframe: At any point between PICU admission and discharge, an average length of 5-7 days and not longer than 60 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Usual Care Group | 15 |
| High Dose Group | 11 |
Hypercalciuria will be identified using calcium:creatinine ratios defined using age-specific norms and thresholds. (NCT01838447)
Timeframe: Immediately before surgery, on admission to the PICU following CHD surgery, and on the first post-operative day
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Enrolment | Intra-operative | Post-Operative Day 1 | |
| High Dose Group | 0 | 4 | 1 |
| Usual Care Group | 1 | 3 | 2 |
2 other studies available for alendronate and Rachitis
| Article | Year |
|---|---|
Response to report of rickets in twins occurring after maternal bisphosphonate exposure.
Topics: Alendronate; Familial Hypophosphatemic Rickets; Female; Humans; Hypercalciuria; Infant, Newborn; Pre | 2020 |
Oral alendronate therapy for severe vitamin D intoxication of the infant with nephrocalcinosis.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Drug Overdose; Female; Humans; | 2006 |